Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Ups and Downs, Industry Attempts To Normalize In Q3

As Indian Pharma Market Continues To Defy International Trends

Executive Summary

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

You may also be interested in...

Nichi-Iko’s Operating Profit Slumps More Than 85% As Price Revisions Bite

Japan’s Nichi-Iko saw its bottom line take a hammering in the six months to 30 September, as a number of its products had their prices cut following revisions to the National Health Insurance program.

Nippon Chemiphar Struggles Despite New Launches

Nippon Chemiphar saw its overall sales drop by 7.9%, dragged down by a fall in generics sales of 9.7%, in its financial first half ended 30 September 2020. The Japanese company’s plan to ride on the success of new launches faltered as it was unable to compensate for the impact of NHI drug price revisions implemented in October 2019 and again in April 2020. 

Sawai Draws On Its Strengths Despite Japanese Pressures

In the face of both local and global pressures, Japan’s Sawai Pharmaceutical is holding steady by relying on its core strengths, company president Kenzo Sawai tells Generics Bulletin in the first part of an exclusive two-part interview.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts